Cardiac Lymphatics in Development and Repair

心脏淋巴管的发育和修复

基本信息

  • 批准号:
    10852321
  • 负责人:
  • 金额:
    $ 25.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-01 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

Abstract With cardiovascular disease the leading cause of death worldwide, valvular heart disease (VHD) currently affects 2.5% of the US population and is one of the most important factors responsible for cardiovascular disease events. Even more surprising, a large-scale clinical study found previously undiagnosed VHD in 50% of the elderly population, further accentuating the need for a better understanding of the pathophysiology of VHDs. However, VHDs remain understudied, and the underlying pathological mechanisms are poorly characterized. Adrenomedullin (AM), a peptide hormone with numerous cardiovascular roles, has been recently shown as the most potent prognostic biomarker in aortic stenosis. Moreover, the AM decoy receptor, Atypical Chemokine Receptor 3 (ACKR3) also attenuates pro-fibrotic signaling and ACKR3-deficient mice display severe valvular defects, including thickened semilunar valves due to increased proliferation of the semilunar valve mesenchymal cells, and develop ventricular fibrosis. Nevertheless, the role of AM and its decoy receptor in cardiac valve development or function has yet not been investigated in detail. With this knowledge in mind, we hypothesize that endothelial and endocardial AM - ACKR3 signaling is a key player in regulating cardiac valvulogenesis and aberrant cardiac fibrosis. Using state-of-the-art light-sheet microscopy, single- cell RNA transcriptomic and animal model approaches, we propose to build on our current expertise GPCR signaling to broad our knowledge on how AM - ACKR3 signaling modulates cardiac health. Our studies will expand our understanding of the underlying molecular mechanisms leading to valvular defects and cardiac fibrosis formation and uncover possible molecular targets for patients with valvular heart diseases.
摘要 心血管疾病是全球死亡的主要原因, (VHD)目前影响着2.5%的美国人口,是最重要的因素之一, 导致心血管疾病事件。更令人惊讶的是,一项大规模的临床研究 在50%的老年人中发现了以前未诊断的VHD,进一步加重了 需要更好地了解VHD的病理生理学。然而,VHD仍然 研究不足,潜在的病理机制也很难描述。 肾上腺髓质素(AM)是一种具有多种心血管作用的肽类激素, 显示为主动脉瓣狭窄中最有效的预后生物标志物。此外,AM诱饵 受体,非典型趋化因子受体3(ACKR 3)也减弱促纤维化信号传导, ACKR 3缺陷小鼠显示严重的瓣膜缺陷,包括由于 增加半月瓣间充质细胞的增殖, 纤维化尽管如此,AM及其诱饵受体在心脏瓣膜发育中的作用, 功能尚未详细研究。有了这些知识,我们假设, 内皮细胞和内皮细胞AM-ACKR 3信号传导在调节心脏的 瓣膜形成和异常心脏纤维化。使用最先进的光片显微镜,单个- 细胞RNA转录组学和动物模型方法,我们建议建立在我们目前的 专业知识GPCR信号转导,以扩大我们对AM-ACKR 3信号转导如何调节 心脏健康我们的研究将扩大我们对潜在分子的理解, 导致瓣膜缺陷和心脏纤维化形成的机制,并揭示可能的 心脏瓣膜病患者的分子靶点。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Innovation and Discovery in Cardiovascular Biology.
心血管生物学的创新与发现。
Lymphatic Function and Dysfunction in the Context of Sex Differences.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kathleen M Caron其他文献

Adrenomedullin and endocrine control of immune cells during pregnancy
妊娠期间肾上腺髓质素和免疫细胞的内分泌控制
  • DOI:
    10.1038/cmi.2014.71
  • 发表时间:
    2014-08-18
  • 期刊:
  • 影响因子:
    19.800
  • 作者:
    Brooke C Matson;Kathleen M Caron
  • 通讯作者:
    Kathleen M Caron

Kathleen M Caron的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kathleen M Caron', 18)}}的其他基金

Illuminating Orphan GPCRs in Lymphatics
阐明淋巴管中的孤儿 GPCR
  • 批准号:
    10216726
  • 财政年份:
    2021
  • 资助金额:
    $ 25.25万
  • 项目类别:
Training Program in Cellular Systems and Integrative Physiology
细胞系统和综合生理学培训计划
  • 批准号:
    10642717
  • 财政年份:
    2020
  • 资助金额:
    $ 25.25万
  • 项目类别:
Training Program in Cellular Systems and Integrative Physiology
细胞系统和综合生理学培训计划
  • 批准号:
    10023779
  • 财政年份:
    2020
  • 资助金额:
    $ 25.25万
  • 项目类别:
Training Program in Cellular Systems and Integrative Physiology
细胞系统和综合生理学培训计划
  • 批准号:
    10205103
  • 财政年份:
    2020
  • 资助金额:
    $ 25.25万
  • 项目类别:
Training Program in Cellular Systems and Integrative Physiology
细胞系统和综合生理学培训计划
  • 批准号:
    10434028
  • 财政年份:
    2020
  • 资助金额:
    $ 25.25万
  • 项目类别:
GPCR-mediated pathways for regulation of intestinal lymphatic function
GPCR 介导的肠道淋巴功能调节途径
  • 批准号:
    9884761
  • 财政年份:
    2019
  • 资助金额:
    $ 25.25万
  • 项目类别:
GPCR-mediated pathways for regulation of intestinal lymphatic function
GPCR 介导的肠道淋巴功能调节途径
  • 批准号:
    10337316
  • 财政年份:
    2019
  • 资助金额:
    $ 25.25万
  • 项目类别:
GPCR-mediated pathways for regulation of intestinal lymphatic function
GPCR 介导的肠道淋巴功能调节途径
  • 批准号:
    10549319
  • 财政年份:
    2019
  • 资助金额:
    $ 25.25万
  • 项目类别:
Cardiac Lymphatics in Development and Repair
心脏淋巴管的发育和修复
  • 批准号:
    10630198
  • 财政年份:
    2016
  • 资助金额:
    $ 25.25万
  • 项目类别:
Cardiac Lymphatics in Heart Failure
心力衰竭中的心脏淋巴管
  • 批准号:
    9417070
  • 财政年份:
    2016
  • 资助金额:
    $ 25.25万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了